Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.350
+0.050 (3.85%)
At close: Nov 22, 2024, 4:00 PM
1.340
-0.010 (-0.74%)
After-hours: Nov 22, 2024, 6:35 PM EST
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,108,975
Market Cap
21.93M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | 1 | 33.33% |
Dec 31, 2021 | 3 | 0 | - |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Bolt Biotherapeutics | 100 |
PolyPid | 62 |
IN8bio | 31 |
Chemomab Therapeutics | 20 |
Tempest Therapeutics | 17 |
NeuroOne Medical Technologies | 16 |
BriaCell Therapeutics | 16 |
AEON Biopharma | 10 |
ACXP News
- 2 days ago - Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook - CNBC
- 2 days ago - Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - PRNewsWire
- 4 days ago - Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update - PRNewsWire
- 9 days ago - Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update - PRNewsWire
- 4 weeks ago - Acurx Ready To Expand Pipeline With Anthrax Treatment - Seeking Alpha
- 4 weeks ago - Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference - PRNewsWire
- 5 weeks ago - Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement - PRNewsWire